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290Effect of Rosuvastatin on Repeat Heart Failure HospitalizationsThe CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure)Objectives This study sought to examine the effect of statin therapy hospitalizations for heart failure (HFH) in patients in the
CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure) trial.Background HFH is an important, frequently recurrent event. Conventional time-to-ﬁrst event analyses do not take account repeat
events. We used a number of statistical approaches to examine the effect of treatment on ﬁrst and repeat HFH in
the CORONA trial.Methods In the CORONA trial, 5,011 patients 60 years of age with chronic New York Heart Association functional classes II
to IV systolic heart failure resulting from ischemia were randomized to receive rosuvastatin or placebo. Poisson,
Andersen-Gill, and negative binomial methods (NB) were used to analyze the effect of rosuvastatin on HFH, and the
NB and a parametric joint frailty model (JF) were used to examine this effect while accounting for the competing risk
of cardiovascular (CV) death. Rosuvastatin/placebo rate ratios were calculated, both unadjusted and adjusted.Results A total of 1,291 patients had 1 or more HFH (750 of these had a single HFH only), and there were a total of 2,408
HFHs. The hazard ratio for the conventional time-to-ﬁrst event analysis for HFH was 0.91 (95% conﬁdence interval
[CI]: 0.82 to 1.02, p ¼ 0.105). In contrast, the NB on repeat hospitalizations gave an unadjusted RR (RR) for HFH of
0.86 (95% CI: 0.75 to 0.99, p¼ 0.030), adjusted 0.82 (95% CI: 0.72 to 0.92, p¼ 0.001), and after including CV death
as the last event, adjusted RR of 0.85 (95% CI: 0.77 to 0.94, p¼ 0.001). The JF gave an adjusted RR of 0.82 (95% CI:
0.73 to 0.92, p ¼ 0.001). Similar results were found in analyses of all CV hospitalizations and all-cause
hospitalizations.Conclusions When repeat events were included, rosuvastatin was shown to reduce the risk of HFH by approximately 15% to 20%,
equating to approximately 76 fewer admissions per 1,000 patients treated over a median 33 months of follow-up.
Including repeat events could increase the ability to detect treatment effects in heart failure trials. (J Am Coll
Cardiol HF 2014;2:289–97) ª 2014 by the American College of Cardiology FoundationThe CORONA (Controlled Rosuvastatin Multinational
Trial in Heart Failure) trial was designed to examine the
effect of statin treatment on the primary composite outcome
of cardiovascular death, myocardial infarction, or stroke in
patients with chronic heart failure and reduced ejection
fraction caused by ischemia (1,2). Rosuvastatin did not reduce
the occurrence of this outcome. However, there were few
myocardial infarctions or strokes and two-thirds of the pri-
mary endpoints were cardiovascular deaths, most of which
were sudden (i.e., presumed to be due to a ventricular
arrhythmia) (2). Therefore, the number of both nonfatal and
fatal events in this composite, amenable to prevention by a
statin, was relatively small, and the primary endpoint may
thus have been insensitive to the effect of rosuvastatin.
Moreover, whereas myocardial infarction and stroke are un-
doubtedly clinically important, they are, arguably, not
as central to the health burden imposed by heart failure,
which is much more frequently manifest as worsening of the
syndrome leading to unplanned hospital admission (3).
Hospitalizations is often recurrent, and there has been recent
interest in assessing the effect of treatment on the total
number of these events (i.e., ﬁrst and repeat events) in clinical
trials (4–6). Therefore, we have carried out a retrospective
analysis of the CORONA trial to explore the effect of rosu-
vastatin on heart failure hospitalizations (HFH) (a pre-
speciﬁed secondary outcome of the trial), including both
ﬁrst and repeat admissions.Methods
Study design and patients. The design and results of
CORONA have been published elsewhere (1,2). Brieﬂy,
CORONA tested the hypothesis that rosuvastatin would
reduce the primary composite outcome of cardiovascular
mortality, nonfatal myocardial infarction, or nonfatal stroke
in patients with chronic symptomatic systolic heart failure
of ischemic origins. A total of 5,011 patients 60 years of
age in New York Heart Association (NYHA) functional
class II, III, or IV were randomized to receive either rosu-
vastatin (10 mg daily) or placebo, in addition to standard
therapy. Secondary outcomes included death from any cause,
any coronary event, death from cardiovascular (CV) causes
and the number of hospitalizations.
Statistical analyses. All analyses were carried out in accor-
dance with the intention-to-treat principle. Baseline char-
acteristics were balanced with respect to treatment group.
Bar plots for the distribution of hospitalizations by treatment
group were created separately for HFH, CV hospitalizations
that were not heart failure, and non-CV hospitalizations.
Cumulative incidence of HFH. The cumulative incidence
of HFH was calculated for each treatment group. The Ghosh
and Lin nonparametric method for calculating the cumula-
tive rate of HFH, while adjusting for mortality was also used
and compared to the crude estimate, which ignores the
competing risk of death (7).
Abbreviations
and Acronyms
ACE = angiotensin-
converting enzyme
ARB = angiotensin-receptor
blocker
CABG = coronary artery
bypass graft
CV = cardiovascular
GFR = glomerular ﬁltration
rate
HFH = heart failure
hospitalization
hsCRP = high-sensitivity
C-reactive protein
NT-pro-BNP = N-terminal
pro-B type natriuretic
peptide
NYHA = New York Heart
Association
PCI = percutaneous coronary
intervention
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291Hospitalization rates. The average number of HFH per
100 patient years was calculated for each treatment group.
The HFH rate per patient year was calculated by dividing
the total number of HFH in each treatment group by the
total number of follow-up years in that group.
Modeling of HFH rates. Recurrent events are typically
analyzed using the Poisson, Andersen-Gill, and negative
binomial methods (8–10). The Poisson and Andersen-Gill
methods assume that all hospitalizations in each treatment
group are independent. This assumption is clearly violated,
as hospitalizations within individuals are associated. Robust
standard errors may be used with the Andersen-Gill method
to account for heterogeneity (11). The negative binomial is
an attractive method because it accommodates heterogeneity
among patients. The negative binomial assumes that each
patient has hospitalizations according to his or her own
individual, speciﬁc event rate through a random effect term
which varies according to a gamma distribution. The
negative binomial regression model was therefore also used
to obtain an estimate of the effect of rosuvastatin in com-
parison to that of placebo on the rate of HFH.
Because an increase in HFH is associated with an increased
risk of subsequent death, any analysis of recurrent admissions
should also allow for CV death as a competing risk. The
negative binomial method was therefore extended by count-
ing each CV death as an additional event. If a patient died
during a HFH, this was counted as a single event. Another
method for incorporating the competing risk of death uses a
parametric joint frailty model to analyze recurrent HFH and
time to CV death simultaneously. This analyses repeat hos-
pitalizations while accounting for the associated mortality risk
(6). The joint model speciﬁes distinct distributions for re-
current hospitalizations and for time to CV death. A com-
mon frailty term, which can be thought of as an unmeasured
indication of the severity of illness that affects both hospi-
talization rate and hazard for CV death, induces an associa-
tion between the 2 processes (12).
Rate ratios, 95% conﬁdence intervals (CIs), and p values
were also calculated using models adjusted for the following
baseline covariates: age, NYHA functional class, ejection
fraction, systolic blood pressure, heart rate, angina pectoris,
diabetes mellitus, atrial ﬁbrillation, pacemaker implant, low-
density lipoprotein, serum creatinine, and N-terminal pro-B
type natriuretic peptide. The multivariate model was built
using those covariates which had univariate associations with
the recurrent HFH at a p value of <0.05. Note that age and
sex were included in the multivariate model, regardless of
signiﬁcance. Sensitivity analyses were performed by means
of unadjusted models.
Results
The frequencies of hospital admissions, without accounting
for differing lengths of follow-up, are presented in Table 1.
Of the 5,011 patients randomized, 1,487 (30%) died, and
3,012 (60%) had at least 1 hospitalization for any cause. Ofthose with at least 1 hospitaliza-
tion, 2,268 (75%) had at least
1 admission for CV causes, with
1,291 patients (57%) with a CV
hospital admission for heart fail-
ure (i.e., 43% of all patients
admitted were hospitalized for
heart failure). There was a total
of 7,768 hospitalizations for any
cause, with 4,757 (61%) being
CV and 2,408 (51%) of those
were due to worsening heart fai-
lure. This means that 31% of all
admissions were HFH.
Including repeat admissions,
there were 1,299 HFH in the
placebo group and 1,109 in the
rosuvastatin group, equating to a
HFH rate of 52.0 and 44.1 per
100 patients in the placebo and
rosuvastatin groups, respectively,
a difference of approximately 8
admissions per 100 patients.
There were 669 patients (27%) in the placebo group and
622 (25%) in the rosuvastatin group, with at least 1 HFH,
equating to a relative risk (RR) of 0.92 (95% CI: 0.84 to
1.01, p ¼ 0.097). This compares to a RR of 0.97 (95% CI:
0.86 to 1.08, p ¼ 0.561) for patients with at least 1 “other”
CV hospitalization (i.e., excluding admissions for worsening
heart failure) and 1.06 (95% CI: 0.93 to 1.22, p ¼ 0.351) for
those with at least 1 non-CV hospitalization. Figure 1 shows
bar plots for the distributions of the frequencies of hospi-
talizations for the different hospitalization types.
Baseline variables associated with hospitalization.
Several baseline characteristics were signiﬁcantly associated
with the risk of being hospitalized at least once for worsening
heart failure (0 vs. 1) (Table 2). Patients more likely to be
hospitalized were older and had a higher NYHA functional
class, heart rate, serum creatinine concentration, N-terminal
pro-B type natriuretic peptide level, and high-sensitivity C-
reactive protein activity. These patients had a lower ejection
fraction, lower systolic blood pressure, diastolic blood pres-
sure, cholesterol level, low-density lipoprotein level, triglyc-
eride level, and estimated glomerular ﬁltration rate (GFR).
They were more likely to have a history of diabetes and atrial
ﬁbrillation and have a pacemaker implanted. Other baseline
characteristics associated with being hospitalized were treat-
ment with a loop diuretic (or a loop or thiazide diuretic), an
aldosterone antagonist, digitalis glycoside, antiarrhythmic
drug, or anticoagulant therapy. Those baseline characteristics
associated with not being hospitalized were treatment with
angiotensin-converting enzyme (ACE) inhibitors, beta-
blockers, or antiplatelet therapy.
Additionally, several baseline characteristics were asso-
ciated with the risk of being hospitalized at least twice
compared with being hospitalized only once for worsening
Table 1 Number of Patients Hospitalized and Number of Hospital Admissions in CORONA
Parameter Placebo Rosuvastatin
Number of patients 2,497 2,514
Total follow-up years 6,201 6,266
Number of deaths 759 728
Number of CV deaths 593 581
All-cause hospitalizations
Patients with 1 admission 1,523 1,489
Patients with 2 admissions 934 883
Number of hospitalizations 4,074 3,694
CV hospitalizations
Patients with 1 admission 1,164 1,104
Patients with 2 admissions 589 534
Number of hospitalizations 2,564 2,193
Heart failure hospitalizations
Patients with 1 admission 669 622
Patients with 2 admissions 295 246
Number of hospitalizations 1,299 1,109
Patients with number of hospitalizations
1 374 376
2 153 134
3 63 58
4 32 24
5 16 13
6 14 6
7 12 4
8 1 2
9 1 2
10 1 2
12 0 1
13 1 0
14 1 0
CORONA ¼ Controlled Rosuvastatin Multinational Trial in Heart Failure; CV ¼ cardiovascular.
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292heart failure. Patients more likely to experience repeat
HFH (exactly 1 vs. 2) were younger, had a higher heart
rate; and higher serum creatinine, N-terminal pro-B typeFigure 1 Hospitalizations per Person
Distributions per person of: 1) the number of heart failure hospitalizations; 2) cardiovascnatriuretic peptide, and high-sensitivity C-reactive protein
and lower ejection fraction, systolic blood pressure, and
cholesterol. They were more likely to be treated with a loopular (CV) hospitalizations that were not heart failure; and 3) non-CV hospitalizations.
Table 2 Baseline Characteristics by Hospitalization Status
Number of Heart Failure Hospitalizations
0 1 2
Age 72.4  7.1 74.0  6.8 72.7  7.3
Females (%) 882 (23.7) 177 (23.6) 121 (22.4)
NYHA functional class (%)
II 1,494 (40.2) 228 (30.4) 135 (25.0)
III 2,186 (58.8) 505 (67.3) 390 (72.1)
IV 40 (1.1) 17 (2.3) 16 (3.0)
Ejection fraction 0.31  0.1 0.30  0.1 0.29  0.1
Body mass index (kg/m2) 27.2  4.5 27.2  4.7 27.3  4.8
Systolic blood pressure 130  16.3 128  16.6 125  17.0
Diastolic blood pressure 76.6  8.9 75.4  8.8 74.6  8.9
Heart rate 70.8  11.0 73.2  11.4 75.2  11.5
Current smokers (%) 409 (11.0) 72 (9.6) 47 (8.7)
No. with the following medical history (%)
Myocardial infarction 2,218 (59.6) 444 (59.2) 342 (63.2)
Angina pectoris 2,676 (71.9) 545 (72.7) 417 (77.1)
CABG or PCI 969 (26.0) 188 (25.1) 141 (26.1)
Hypertension 2,341 (62.9) 478 (63.7) 356 (65.8)
Diabetes mellitus 1,010 (27.2) 265 (35.3) 202 (37.3)
Atrial ﬁbrillation 1,399 (37.6) 382 (50.9) 273 (50.5)
Stroke 446 (12.0) 100 (13.3) 78 (14.4)
Pacemaker implanted 357 (9.6) 111 (14.8) 93 (17.2)
Implantable cardioverter-deﬁbrillator 105 (2.8) 17 (2.3) 14 (2.6)
Laboratory measurements
Cholesterol 5.41  1.1 5.25  1.1 5.09  1.1
Low-density lipoprotein 3.60  0.9 3.47  0.9 3.35  0.9
High-density lipoprotein 1.24  0.3 1.22  0.4 1.21  0.4
ApoB/ApoA-I ratio 0.87  0.2 0.87  0.3 0.87  0.3
Triglycerides 2.03  1.3 1.96  1.2 1.85  1.4
Serum creatinine 114  27.3 118  28.7 123  30.8
Estimated GFR 58.2  14.3 55.5  14.2 53.8  14.6
NT-pro-BNP 173 [88; 231] 173 [154; 386] 199 [173; 512]
hsCRP 3.20 [1.5; 6.9] 4.00 [1.8; 7.9] 5.20 [2.4; 10.3]
No. of patients currently taking the following medications (%)
Loop diuretic 2,649 (71.2) 640 (85.3) 500 (92.4)
Loop or thiazide diuretic 3,201 (86.0) 693 (92.4) 522 (96.5)
Aldosterone antagonist 1,346 (36.2) 331 (44.1) 288 (53.2)
ACE inhibitor 2,998 (80.6) 596 (79.5) 417 (77.1)
ACE inhibitor or ARB 3,432 (92.3) 683 (91.1) 484 (89.5)
Beta-blocker 2,849 (76.6) 524 (69.9) 393 (72.6)
Digitalis glycoside 1,107 (29.8) 301 (40.1) 240 (44.4)
Antiarrhythmic therapy 425 (11.4) 114 (15.2) 85 (15.7)
Antiplatelet therapy 2,271 (61.0) 409 (54.5) 292 (54.0)
Anticoagulant therapy 1,235 (33.2) 308 (41.1) 224 (41.4)
Antiplatelet or anticoagulant therapy 3,344 (89.9) 683 (91.1) 497 (91.9)
Values are mean  SD, n (%), or mean [interquartile range].
ACE ¼ angiotensin-converting enzyme; Apo ¼ apolipoprotein; ApoA-I ¼ apolipoprotein A-inhibitor; Apo-ARB ¼ angiotensin-receptor blocker; CABG ¼ coronary
artery bypass graft; GFR ¼ glomerular ﬁltration rate; hsCRP ¼ high-sensitivity C-reactive protein; NT-pro-BNP ¼ N-terminal pro-B type natriuretic peptide;
NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention.
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293diuretic (or loop or thiazide diuretic) and an aldosterone
antagonist.
A multivariate model was also used to identify indepen-
dent predictors of admission, as described later (Table 3).
During the trial, 71 patients (31 rosuvastatin/40 placebo)
had an acute myocardial infarction preceding a subsequent
HFH. Therefore, 1,220 patients (591 rosuvastatin/629placebo) experienced a HFH that was not preceded by a
myocardial infarction during the trial.
Cumulative incidence of HFH. The cumulative crude
numbers of HFH per 100 patients in the 2 treatment
groups are shown in Figure 2. The cumulative incidence
curves did not seem to diverge until approximately 12
months but continued to separate thereafter. To
Table 3
Variables Associated With Heart Failure Hospitalization Rates (Rate Ratio, 95% CI,
and p Value) in the Multivariate Negative Binomial Regression Model
Rate Ratio 95% CI p Value
Rosuvastatin versus placebo 0.815 0.72–0.92 0.001
Age* 1.007 0.94–1.08 0.834
Female 1.083 0.93–1.27 0.316
NYHA class (compared to class II)
III 1.515 1.32–1.74 <0.001
IV 2.146 1.35–3.40 0.001
Ejection fraction* 0.803 0.75–0.86 <0.001
Systolic blood pressure* 0.853 0.80–0.91 <0.001
Heart rate* 1.268 1.19–1.35 <0.001
Medical history
Angina pectoris 1.291 1.12–1.49 <0.001
Diabetes mellitus 1.553 1.36–1.78 <0.001
Atrial ﬁbrillation 1.350 1.19–1.54 <0.001
Pacemaker implanted 1.321 1.10–1.59 0.003
Laboratory measurements
LDL cholesterol* 0.882 0.83–0.94 <0.001
Serum creatinine* 1.213 1.14–1.29 <0.001
NT-pro-BNP* 1.404 1.33–1.48 <0.001
*Rate ratio is per 1-SD increase.
CI ¼ conﬁdence interval; LDL ¼ low-density lipoprotein; NT-pro-BNP ¼ N-terminal pro-B type natriuretic peptide; NYHA ¼ New York Heart
Association.
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294incorporate the competing risk of death, the Ghosh and
Lin approach was also plotted (Fig. 2). The Ghosh and Lin
rates were consistently lower than the cumulative incidence
ones, but the separation between the treatment groups
appeared to occur at the same time and to the same extent.Figure 2 Rate of Heart Failure Hospitalizations
Estimated cumulative rate of heart failure hospitalizations per 100 patients
over time, by treatment group and statistical method.Because there were no between-treatment differences in
CV death (Fig. 3), use of the Ghosh and Lin approach
made a negligible difference to the effect of rosuvastatin on
hospitalization. Figure 4 shows the ratio of the crude cu-
mulative numbers of HFH for the rosuvastatin group
compared with that of placebo. This ratio remained
approximately 1 for the ﬁrst year before decreasing toFigure 3 Cardiovascular Death
Kaplan-Meier curves for CV death (rosuvastatin vs. placebo).
Figure 4 Cumulative Incidence
Ratio (rosuvastatin vs. placebo) of the cumulative incidence of heart failure
hospitalizations over time.
Figure 5 Comparison of Results From Different Methods
Unadjusted hazard ratio for conventional (Cox) time to ﬁrst event analyzes of heart
failure hospitalization (HFH), as well as rate ratios for the Poisson, Andersen-Gill,
and negative binomial analyses of all HFH; negative binomial for the composite of
all HFHs and CV (CV) death and the rate ratio for all HFHs from the joint frailty
model.
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295approximately 0.85 by 1.5 years, after which it appeared
fairly constant.
Modeling of HFH rates. In the placebo group there were
1,299 HFH over 6,201 years of follow-up, in comparison
with 1,109 HFH over 6,266 years of follow-up in the
rosuvastatin group. Thus, HFH rates in the placebo and
rosuvastatin groups were 21.0 and 17.7 per 100 patient
years, respectively, giving a rate ratio of 0.84 (95% CI: 0.78
to 0.92, p < 0.001).
The negative binomial regression model gave an unad-
justed rate ratio for HFH in the rosuvastatin group compared
with the placebo group of 0.86 (95% CI: 0.75 to 0.99,
p ¼ 0.030). Table 3 shows results from the multivariate
negative binomial regression model examining the associa-
tion between baseline covariates and HFH rates. In addition
to rosuvastatin treatment, baseline covariates independently
associated with increased HFH rates were: being female,
history of angina pectoris, diabetes, atrial ﬁbrillation and an
implanted pacemaker, higher NYHA functional class, heart
rate, serum creatinine and N-terminal pro-B type natriuretic
peptide, a lower ejection fraction, lower systolic blood pres-
sure, and lower low-density lipoprotein (LDL) cholesterol.
The rate ratio for rosuvastatin, adjusted for baseline cova-
riates, was 0.81 (95% CI: 0.72 to 0.92, p ¼ 0.001).
Rates of CV hospitalizations (both for heart failure and
other CV reasons) and hospitalizations for any cause were
also analyzed using the negative binomial regression model.
The rate ratio for CV hospitalizations for rosuvastatin, as
compared with placebo, was unadjusted 0.85 (95% CI: 0.77
to 0.93, p ¼ 0.001) and 0.83 adjusted for the same covariates(95% CI: 0.76 to 0.91, p < 0.001). For all-cause hospital-
izations, the rate ratio was unadjusted 0.90 (95% CI: 0.83 to
0.97, p ¼ 0.009) and 0.89 adjusted (95% CI: 0.83 to 0.96,
p ¼ 0.002).
The negative binomial regression model was also used
to analyze the composite of recurrent HFH and CV death,
where CV death was treated as an additional event. This
gave a rate ratio for rosuvastatin, compared with placebo,
of 0.88 (95% CI: 0.79 to 0.98, p ¼ 0.025). An adjusted
analysis gave a rate ratio of 0.85 (95% CI: 0.77 to 0.94,
p ¼ 0.001).
A joint frailty model was also used to estimate the
recurrent HFH rate ratio, taking into account CV death as
informative censoring and an estimate for the hazard ratio
for CV death taking into account the impact of hospitali-
zations. This approach gave an estimated rosuvastatin/pla-
cebo rate ratio of 0.86 (95% CI: 0.75 to 0.98, p ¼ 0.028) for
HFH. The estimated hazard ratio for CV death in the
rosuvastatin group, compared with placebo, was 0.99 (95%
CI: 0.85 to 1.16, p ¼ 0.890). Analyses adjusted for baseline
covariates gave a rate ratio for HFH of 0.82 (95% CI: 0.73
to 0.92, p ¼ 0.001) and a hazard ratio for CV death of 0.94
(95% CI: 0.82 to 1.09, p ¼ 0.423).
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296In summary, Figure 5 shows the hazard ratio for the
conventional time-to-ﬁrst event analysis for HFH (0.91
[95% CI: 0.82 to 1.02, p¼ 0.105]) and the rate ratios for the
Poisson and Andersen-Gill results for the HFH and nega-
tive binomial models for the HFH and the composite of
recurrent HFH and CV death, along with the estimated
rate ratio from the joint frailty model.
Discussion
In this retrospective analysis, we found evidence that treat-
ment with rosuvastatin causes a highly signiﬁcant reduction
in the overall incidence of hospitalizations for worsening
heart failure in the CORONA trial, although the effect size
was modest.
As in other recent reports, we showed that ﬁrst hospitali-
zations (the only admissions counted in conventional time-to-
ﬁrst analyses) represented just over one-half of such events.
Speciﬁcally, 1,291 patients had 1 or more admissions for heart
failure (750 of these had a single admission only), and there
were a total of 2,408 admissions for heart failure. Therefore,
1,291 of 2,408 hospitalizations for heart failure in CORONA
(54%) were ﬁrst admissions, a remarkably similar proportion
to that in the SHIFT (56%), EMPHASIS-HF (58%), and
CHARM-Preserved (54%) studies (4–6).
The effect of rosuvastatin on second or subsequent hos-
pital admissions was at least as large as on the ﬁrst admis-
sion. This explains why the present analysis of all events (as
opposed to just ﬁrst events) had more power to demonstrate
a signiﬁcant beneﬁt from rosuvastatin. Three other recent
analyzes also showed a beneﬁcial effect of the treatments
studied (ivabradine, eplerenone, and candesartan) on repeat
as well as on ﬁrst events (4–6).
What was different in the present study was that the beneﬁt
of ivabradine, eplerenone, and candesartan was rapid onset,
whereas that of rosuvastatin seemed to be delayed for almost a
year (4–6). This probably contributed to the modest overall
treatment effect size and may also explain why the anticipated
beneﬁt on CV mortality (because HFH is associated with an
increased risk of death and usually a reduction in the former is
associated with a reduction in the latter) was not observed;
that is, any beneﬁcial effect on reducing mortality might have
been delayed and not demonstrable within the time frame of
the CORONA trial.
Although the effect of rosuvastatin was not as large as
with the other treatments mentioned, its use in CORONA
did prevent approximately 80 fewer admissions for heart
failure per 1,000 patients treated over a median of 33
months of follow-up. This compares with 93 admissions
(over 23 months), 122 admissions (over 25 months), and
104 admissions (over 37 months) prevented per 1,000 pa-
tients treated with ivabradine in SHIFT, eplerenone in
EMPHASIS-HF, and candesartan in CHARM-Preserved
studies, respectively (4–6).
These ﬁndings obviously raise questions about possible
mechanisms underlying the effect of rosuvastatin on HFH(and why the effect might take time to become manifest).
One obvious explanation is prevention of myocardial in-
farction (in turn leading to prevention of worsening heart
failure). Relatively few patients (n ¼ 71) suffered an
endpoint committee-conﬁrmed event of this type, and,
although numerically fewer in the rosuvastatin group (n ¼
31) versus placebo (n ¼ 40), the difference between treat-
ments was not signiﬁcant and could not have accounted for
the difference in HFH observed (2). It is possible, however,
that smaller, “subclinical,” infarcts were prevented by rosu-
vastatin. However, rosuvastatin did not reduce troponin
levels in a substudy of CORONA (13). Alternatively, there
has been much interest in the so-called pleiotropic effects of
statins, the best recognized of which is an anti-inﬂammatory
action. Certainly, rosuvastatin reduced plasma hsCRP con-
centrations in CORONA (2), although in a substudy, it did
not affect the levels of other cytokines (14).
Whatever the mechanism of action, the beneﬁt observed,
although modest, is clinically worthwhile given that it is in-
cremental (i.e., additional to the beneﬁts of standard treat-
ments), that the treatment in question is a generic and
inexpensive one and that statins are very well tolerated in pa-
tients with heart failure, with high-quality safety data available
from 2 large placebo-controlled randomized trials (2,15).
Current guidelines correctly do not recommend statins in heart
failure based upon appropriately strict interpretation of the
primary analyses of the 2 key randomized trials (16,17). We
believe that these new results should lead to further assessment
of the role of statins in ischemic, systolic, heart failure.
On a more methodological note, the summary of ﬁnd-
ings in Figure 5 shows how the use of all HFH (including
repeat events) could enhance the ability to detect treat-
ment differences compared with the Cox model using ﬁrst
hospitalization only. The Poisson method should not be
used because it naively treats all hospitalizations as equally
important and gives a false sense of precision in its esti-
mates of rate ratio by failing to account for the hetero-
geneity in individual patient risks of repeat events. The
other methods (negative binomial, Andersen-Gill with
robust standard errors, and joint frailty model) show a
consistency of ﬁndings, directly accounting for the skewed
distribution of hospitalizations and toning down the in-
ﬂuence of those patients with many hospitalizations. For
future heart failure trials, we would encourage greater use
of such repeat event analyses as they enhance statistical
power and they capture the total disease burden with
regards to HFH.
Study limitations. Our report has a number of limitations.
First, we looked at outcomes other than the primary
endpoint. Although we believe analysis of repeat events is
important, it has not been the standard approach used in
most CV trials to date. Although we have shown that
rosuvastatin appears to reduce HFH, we do not have a
good explanation for this effect (or its time course). All
patients in CORONA had systolic heart failure from
ischemic causes, and we do not know whether the
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heart failure (and another trial suggests it might not be
[15]) or in patients with heart failure and preserved ejection
fraction. It should be noted that 3,720 of the 5,011 (74%)
patients randomized did not have any HFH during follow-
up, resulting in a large number of zeros in the dataset. The
negative binomial distribution is commonly used to analyze
such skewed distributions as an alternative to zero-inﬂated
models (18).
Conclusions
In older patients with ischemic systolic heart failure, treat-
ment with rosuvastatin led to an approximateRR reduction of
15% to 20% in total HFH, equating to an absolute reduction
of approximately 76 fewer admissions for heart failure per
1,000 patients treated over a median of 33 months of follow-
up. Although modest, this beneﬁt is potentially clinically
worthwhile and should lead to further investigation of the role
of statins in ischemic systolic heart failure.
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